Digestive Diseases and Sciences

, Volume 57, Issue 5, pp 1321–1329 | Cite as

The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome

  • Emmannouil Pyleris
  • Evangelos J. Giamarellos-BourboulisEmail author
  • Dimitrios Tzivras
  • Vassilios Koussoulas
  • Charalambos Barbatzas
  • Mark Pimentel
Original Article



Many studies have linked irritable bowel syndrome (IBS) with small intestinal bacterial overgrowth (SIBO), although they have done so on a qualitative basis using breath tests even though quantitative cultures are the hallmark of diagnosis. The purpose of this study was to underscore the frequency of SIBO in a large number of Greeks necessitating upper gastrointestinal (GI) tract endoscopy by using quantitative microbiological assessment of the duodenal aspirate.


Consecutive subjects presenting for upper GI endoscopy were eligible to participate. Quantitative culture of aspirates sampled from the third part of the duodenum during upper GI tract endoscopy was conducted under aerobic conditions. IBS was defined by Rome II criteria.


Among 320 subjects enrolled, SIBO was diagnosed in 62 (19.4%); 42 of 62 had IBS (67.7%). SIBO was found in 37.5% of IBS sufferers. SIBO was found in 60% of IBS patients with predominant diarrhea compared with 27.3% without diarrhea (P = 0.004). Escherichia coli, Enterococcus spp and Klebsiella pneumoniae were the most common isolates within patients with SIBO. A step-wise logistic regression analysis revealed that IBS, history of type 2 diabetes mellitus and intake of proton pump inhibitors were independently and positively linked with SIBO; gastritis was protective against SIBO.


Using culture of the small bowel, SIBO by aerobe bacteria is independently linked with IBS. These results reinforce results of clinical trials evidencing a therapeutic role of non-absorbable antibiotics for the management of IBS symptoms.


Irritable bowel syndrome Intestinal bacterial overgrowth Diabetes mellitus Proton pump inhibitors 



The study was funded in part by a kind donation by Vianex SA, Greece. The study was funded in part by an unrestricted educational grant by Alfa Wassermann, Alanno, Italy.

Conflict of interest

E.P, E.J.G.B., D.T., V.K. and C.B. have no conflict of interest to declare in relationship with this submission. M.P. is funded by the Beatrice and Samuel A. Seaver Foundation, he is a consultant for Salix Pharmaceuticals, has grant funding from Salix Pharmaceuticals and Cedars-Sinai Medical Center has a licensing agreement with Salix.


  1. 1.
    Katsinelos P, Lazaraki G, Kountouras J, et al. Prevalence, bowel habit subtypes and medical care-seeking behavior of patients with irritable bowel syndrome in Northern Greece. Eur J Gastroenterol Hepatol. 2009;21:183–189.PubMedCrossRefGoogle Scholar
  2. 2.
    Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51:1–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Riordan SM, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol. 2006;22:669–673.PubMedCrossRefGoogle Scholar
  4. 4.
    Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160.PubMedCrossRefGoogle Scholar
  5. 5.
    Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;2:1391–1395.CrossRefGoogle Scholar
  6. 6.
    Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2241–2249.CrossRefGoogle Scholar
  7. 7.
    Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334–340.PubMedCrossRefGoogle Scholar
  8. 8.
    Welin L, Adlerberth A, Caidahl K, et al. Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-age women and women in Gothenburg, Sweden. BMC Public Health. 2009;8:403.CrossRefGoogle Scholar
  9. 9.
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:1143–1147.Google Scholar
  10. 10.
    Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002;122:1701–1714.PubMedCrossRefGoogle Scholar
  11. 11.
    Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305–311.PubMedCrossRefGoogle Scholar
  12. 12.
    Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781–786.PubMedCrossRefGoogle Scholar
  13. 13.
    Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol. 2009;15:2628–2631.PubMedCrossRefGoogle Scholar
  14. 14.
    Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326–333.PubMedCrossRefGoogle Scholar
  16. 16.
    Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a non-absorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145:557–563.PubMedGoogle Scholar
  17. 17.
    Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8:401–409.PubMedCrossRefGoogle Scholar
  19. 19.
    Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2011;10:23.CrossRefGoogle Scholar
  20. 20.
    Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol. 2011;26:135–138.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44:672–675.PubMedCrossRefGoogle Scholar
  22. 22.
    Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.PubMedCrossRefGoogle Scholar
  23. 23.
    Ghoshal UC, Ghoshal U, Ayyagari A, et al. Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time. J Gastroenterol Hepatol. 2003;18:540–547.PubMedCrossRefGoogle Scholar
  24. 24.
    Spiegel BMR, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103:2972–2976.PubMedCrossRefGoogle Scholar
  25. 25.
    Quigley EMM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis. 2007;8:2–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Emmannouil Pyleris
    • 1
  • Evangelos J. Giamarellos-Bourboulis
    • 2
    • 4
    Email author
  • Dimitrios Tzivras
    • 2
  • Vassilios Koussoulas
    • 1
  • Charalambos Barbatzas
    • 1
  • Mark Pimentel
    • 3
  1. 1.Department of GastroenterologySismanogleion General HospitalAthensGreece
  2. 2.4th Department of Internal MedicineUniversity of Athens, Medical SchoolAthensGreece
  3. 3.GI Motility Program, Cedars-Sinai Medical CenterLos AngelesUSA
  4. 4.4th Department of Internal MedicineATTIKON University HospitalAthensGreece

Personalised recommendations